SSRI use in pregnancy does not increase the risk of stillbirth, neonatal mortality or post-neonatal mortality

Newborn baby and mother

Studies have shown that the prevalence of depression in pregnant women is 7-19%. Being depressed during pregnancy can result in preterm delivery, which can in turn lead to illness and even death of the newborn child.

Researchers have struggled to single out the causes of these risks. Is it the depression, the medical treatment being given (e.g. antidepressants), or possibly other underlying issues like substance misuse or stress?

Less severe depression is usually managed with non-drug treatments, but major depression sometimes requires antidepressant medication, which does of course come with known side effects. The evidence is far from clear cut, but studies over the last 8 years have suggested that SSRI (selective serotonin reuptake inhibitor) antidepressant use during pregnancy is associated with congenital anomalies, spontaneous abortion, neonatal withdrawal syndrome and persistent pulmonary hypertension in the newborn child.

These risks may well drive expectant mothers to stop taking their antidepressants, but of course this behaviour comes with a new set of risks as maternal mental illness is also associated with problems for young children, particularly infant death syndrome.

We are still pretty much in the dark about some of the other risk factors in pregnancy and the influence that SSRIs may have on them, so a new population-based cohort study published in JAMA is important evidence that can help fill the gap. The authors of this study focused on the influence that SSRI use has on risk of stillbirth, neonatal and infant death.


The reviewers used data from Denmark, Finland, Iceland, Norway, and Sweden, where comprehensive information about maternal use of SSRIs from prescription registries is easily available. They included women pregnant with one baby and used data from patient and medical birth registries to measure maternal characteristics, pregnancy and neonatal outcomes.

There were 1,633,877 single births including in the study, including 6,054 stillbirths, 3,609 neonatal deaths and 1,578 post-neonatal deaths.

1.79% of mothers in the study had picked up a prescription for SSRIs during the pregnancy.


  • Compared with those who were not prescribed antidepressants, women exposed to an SSRI presented with:
    • Higher rates of stillbirth (4.62 vs 3.69 per 1000, P=.01)
    • Higher rates of post-neonatal death (1.38 vs 0.96 per 1000, P=.03)
    • Similar rates of neonatal death (2.54 vs 2.21 per 1000, P = .24)
  • However, in multivariable models, SSRI use was not associated with:
    • Stillbirth (adjusted odds ratio [OR], 1.17; 95% CI, 0.96-1.41; P = .12)
    • Neonatal death (adjusted OR, 1.23; 95% CI, 0.96-1.57; P = .11)
    • Post-neonatal death (adjusted OR, 1.34; 95% CI, 0.97-1.86; P = .08)
  • The adjusted OR for stillbirth was:
    • 0.92 (95% CI, 0.66-1.28; P = .62) in women with a previous hospitalisation for psychiatric disease
    • 1.07 (95% CI, 0.84-1.36; P = .59) for those who had not been previously hospitalised
  • The corresponding ORs for neonatal death were:
    • 0.89 (95% CI, 0.58-1.39; P=.62) for women who were hospitalised
    • 1.14 (95% CI, 0.84-1.56; P = .39) for women who were not
  • For post-neonatal death, the ORs were:
    • 1.02 (95% CI, 0.61-1.69; P = .95) for women who were hospitalised
    • 1.10 (95% CI, 0.71-1.72; P = .66) for women who were not


The authors concluded:

Among women with singleton births in Nordic countries, no significant association was found between use of SSRIs during pregnancy and risk of stillbirth, neonatal mortality, or post-neonatal mortality.

However, decisions about use of SSRIs during pregnancy must take into account other perinatal outcomes and the risks associated with maternal mental illness.

The study showed that the increased rates of stillbirth and post-neonatal mortality in babies exposed to SSRIs were explained by the severity of the underlying mental illness affecting their mothers, higher rates of smoking and higher maternal age.

This is a large and well conducted study that provides us with reliable data that can be used to help care for pregnant women and their babies.


Stephansson O, Kieler H, Haglund B, Artama M, Engeland A, Furu K, Gissler M, Nørgaard M, Nielsen RB, Zoega H, Valdimarsdóttir U. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA. 2013 Jan 2;309(1):48-54. doi: 10.1001/jama.2012.153812. [PubMed abstract]

Share on Facebook Tweet this on Twitter Share on LinkedIn Share on Google+
Mark as read
Create a personal elf note about this blog
Profile photo of Andre Tomlin

Andre Tomlin

André Tomlin is an Information Scientist with 20 years experience working in evidence-based healthcare. He's worked in the NHS, for Oxford University and since 2002 as Managing Director of Minervation Ltd, a consultancy company who do clever digital stuff for charities, universities and the public sector. Most recently André has been the driving force behind the Mental Elf and the National Elf Service; an innovative digital platform that helps professionals keep up to date with simple, clear and engaging summaries of evidence-based research. André is a Trustee at the Centre for Mental Health and an Honorary Research Fellow at University College London Division of Psychiatry. He lives in Bristol, surrounded by dogs, elflings and lots of woodland!

More posts - Website

Follow me here –